Adult T-cell Lymphoma/Leukaemia Refractory

Adult T-cell lymphoma/leukaemia that stops responding to treatment poses one of the most challenging situations in blood cancer care, with patients facing limited options and urgent need for new therapeutic approaches.

Table of contents

• What Is Refractory Adult T-cell Lymphoma/Leukaemia
• Understanding Treatment Response
• Treatment Options for Refractory Disease
• Survival Outcomes
• Emerging Treatment Approaches

What Is Refractory Adult T-cell Lymphoma/Leukaemia

Adult T-cell lymphoma/leukaemia (ATL) is a rare and aggressive cancer of the blood and lymph system that develops in people infected with human T-cell lymphotropic virus type 1 (HTLV-1), a virus that infects specialized white blood cells called T-cells. The term refractory describes when the lymphoma does not respond to treatment, meaning that the cancer cells continue to grow despite therapy, or when the response to treatment does not last very long.^[4]

ATL is particularly challenging because it often shows chemo-resistance, which means the malignant cells do not respond well to standard chemotherapy drugs. This resistance, combined with severe weakening of the immune system, leads to poor outcomes for patients who have rapidly progressive disease.^[1]

The disease is most common in regions where HTLV-1 infection is widespread, including southwestern Japan, the Caribbean, West Africa, and parts of Central and South America. In North America, ATL is rarely reported, with an incidence rate of only 0.06 per 100,000 population between 2001 and 2015.^[1]

Understanding Treatment Response

When ATL is described as refractory, it means the disease is not responding to current treatment approaches. This can happen in two main ways. First, the cancer may continue to grow even during initial treatment, showing no reduction in tumor size or cancer cell numbers. Second, the disease may initially respond to treatment but then quickly return, often within a short period after therapy ends.^[4]

The aggressive subtypes of ATL, which include acute and lymphomatous forms, are particularly prone to becoming refractory. These forms carry extremely poor prognosis, with median overall survival (the time at which half of patients are still alive) of approximately 9 to 13 months, and this timeframe has remained largely unchanged over the past 40 years despite advances in cancer treatment.^[5]

Unlike many other blood cancers, most patients with aggressive ATL cannot be cured with current chemotherapy approaches. Many patients experience disease that either does not respond to initial treatment or returns shortly after therapy.^[4]

Treatment Options for Refractory Disease

There is no established standard treatment for refractory ATL, which makes managing this condition particularly challenging. Many chemotherapy combinations used to treat other types of T-cell lymphomas after disease returns are also being used to treat refractory ATL.^[4]

Common chemotherapy regimens include DHAP (dexamethasone, cytarabine, and cisplatin), ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin), GDP (gemcitabine, dexamethasone, and cisplatin), and ICE (ifosfamide, carboplatin, and etoposide).^[4]

Two targeted therapy drugs have been used in the relapsed or refractory setting. Pralatrexate (Folotyn) and belinostat (Beleodaq) are medications specifically designed to treat T-cell lymphomas and have been tried in patients whose ATL has returned or stopped responding to other treatments.^[4]

Mogamulizumab, an antibody that targets a protein called CCR4 found on the surface of ATL cells, has been the most frequently studied treatment for relapsed and refractory disease. This medication was approved in Japan based on phase II clinical trial results. Studies have shown that mogamulizumab treatment can potentially provide longer survival compared with chemotherapy alone.^[6]

For patients who show some response to treatment, allogeneic stem cell transplantation (a procedure where healthy blood-forming cells from a donor are given to the patient) may be considered. This approach can potentially provide longer-lasting disease control, though it carries significant risks and is only suitable for selected patients who are healthy enough to undergo the procedure.^[4][6]

Survival Outcomes

A comprehensive review of survival outcomes for relapsed or refractory ATL examined 21 different treatment groups from 14 studies. The results showed considerable variation in how long patients survived, depending on the type of treatment received.^[6]

For patients treated with mogamulizumab, median overall survival ranged from 2.2 to 17.6 months across different studies. For patients who received mogamulizumab before undergoing stem cell transplantation, median survival ranged from 3.8 to 6.2 months. Those who received stem cell transplantation had median survival times between 3.8 and 6.2 months, while other chemotherapy approaches showed median survival ranging from 4.1 to 20.3 months.^[6]

These wide ranges in survival times reflect the complexity of the disease and the challenges in comparing different treatments when patients have varying disease characteristics and overall health conditions. The variation also highlights the urgent need for clinical trials to better understand which treatments work best for specific patient populations.^[6]

Emerging Treatment Approaches

Because current treatments for refractory ATL are largely ineffective, researchers are exploring new therapeutic strategies. One promising area involves targeting specific biological pathways that cancer cells use to survive and grow.^[9]

Recent case reports have shown encouraging results with venetoclax, a medication that blocks a protein called Bcl-2, which helps cancer cells avoid normal cell death. Two patients with primary refractory ATL who received venetoclax experienced significant declines in their HTLV-1 viral load and achieved complete remission. These patients had genetic testing that confirmed the presence of mutations in BCL2 and other cancer-related genes, which may have made them more likely to respond to this targeted therapy.^[9]

This finding suggests that using next-generation sequencing (advanced genetic testing that can identify specific mutations in cancer cells) might help doctors select the most appropriate treatments for individual patients. By understanding which genetic changes are present in a patient’s cancer cells, physicians may be able to choose therapies that target those specific abnormalities.^[9]

Enrollment in clinical trials remains a critical option for patients with relapsed or refractory ATL. These trials test new medications and treatment combinations that may offer better outcomes than currently available therapies. Given the poor results with standard treatments, participation in clinical trials provides access to potentially more effective approaches while also contributing to medical knowledge that may help future patients.^[4][7]